United Kingdom

People: Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

3:39pm BST
Change (% chg)

€0.66 (+6.07%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Duncan, Carri 

Dr. Carri Duncan has been appointed Vice President Corporate Development and Communications of Celyad SA as of October 1, 2018. Recently, she served as VP Investor Relations at Bayer. Prior to that, she worked at Egon Zehnder as a Management Consultant in the Life Science and Finance practice groups. In previous years, she worked as an equities analyst including on the Buy-side at Credit Suisse, where she has pioneered coverage of European Biotech equities. For over a decade, Ms. Duncan worked as a molecular and cell biologist in academia and with Novartis and Eli Lilly in areas of developmental biology and cancer research, respectively. She earned a PhD in Neuroscience from the ETH-Zurich.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --